Switch theme
Sign up to access all valuation multiples
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
n/a
LTM Revenue $5.3M
LTM EBITDA -$31.7M
$83.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Maat Pharma has a last 12-month revenue (LTM) of $5.3M and a last 12-month EBITDA of -$31.7M.
In the most recent fiscal year, Maat Pharma achieved revenue of $3.6M and an EBITDA of -$29.6M.
Maat Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Maat Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.3M | XXX | $3.6M | XXX | XXX | XXX |
| Gross Profit | $4.1M | XXX | $2.2M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | -$31.7M | XXX | -$29.6M | XXX | XXX | XXX |
| EBITDA Margin | -599% | XXX | -819% | XXX | XXX | XXX |
| EBIT | -$29.9M | XXX | -$31.9M | XXX | XXX | XXX |
| EBIT Margin | -566% | XXX | -884% | XXX | XXX | XXX |
| Net Profit | -$32.6M | XXX | -$32.5M | XXX | XXX | XXX |
| Net Margin | -616% | XXX | -899% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Maat Pharma's stock price is EUR 5 (or $5).
Maat Pharma has current market cap of EUR 78.2M (or $87.8M), and EV of EUR 73.9M (or $83.0M).
See Maat Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $83.0M | $87.8M | XXX | XXX | XXX | XXX | $-2.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Maat Pharma has market cap of $87.8M and EV of $83.0M.
Maat Pharma's trades at 23.0x EV/Revenue multiple, and -2.8x EV/EBITDA.
Equity research analysts estimate Maat Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Maat Pharma has a P/E ratio of -2.7x.
See valuation multiples for Maat Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $87.8M | XXX | $87.8M | XXX | XXX | XXX |
| EV (current) | $83.0M | XXX | $83.0M | XXX | XXX | XXX |
| EV/Revenue | 15.7x | XXX | 23.0x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | -2.8x | XXX | XXX | XXX |
| EV/EBIT | -2.8x | XXX | -2.6x | XXX | XXX | XXX |
| EV/Gross Profit | 20.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.7x | XXX | -2.7x | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | -3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMaat Pharma's last 12 month revenue growth is 195%
Maat Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Maat Pharma's rule of 40 is -633% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Maat Pharma's rule of X is -111% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Maat Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 195% | XXX | 173% | XXX | XXX | XXX |
| EBITDA Margin | -599% | XXX | -819% | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -633% | XXX | -624% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -111% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 854% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 945% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Maat Pharma acquired XXX companies to date.
Last acquisition by Maat Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Maat Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Maat Pharma headquartered? | Maat Pharma is headquartered in France. |
| Is Maat Pharma publicy listed? | Yes, Maat Pharma is a public company listed on PAR. |
| What is the stock symbol of Maat Pharma? | Maat Pharma trades under MAAT ticker. |
| When did Maat Pharma go public? | Maat Pharma went public in 2021. |
| Who are competitors of Maat Pharma? | Similar companies to Maat Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Maat Pharma? | Maat Pharma's current market cap is $87.8M |
| What is the current revenue of Maat Pharma? | Maat Pharma's last 12 months revenue is $5.3M. |
| What is the current revenue growth of Maat Pharma? | Maat Pharma revenue growth (NTM/LTM) is 195%. |
| What is the current EV/Revenue multiple of Maat Pharma? | Current revenue multiple of Maat Pharma is 15.7x. |
| Is Maat Pharma profitable? | Yes, Maat Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Maat Pharma? | Maat Pharma's last 12 months EBITDA is -$31.7M. |
| What is Maat Pharma's EBITDA margin? | Maat Pharma's last 12 months EBITDA margin is -599%. |
| What is the current EV/EBITDA multiple of Maat Pharma? | Current EBITDA multiple of Maat Pharma is -2.6x. |
| What is the current FCF of Maat Pharma? | Maat Pharma's last 12 months FCF is -$27.0M. |
| What is Maat Pharma's FCF margin? | Maat Pharma's last 12 months FCF margin is -511%. |
| What is the current EV/FCF multiple of Maat Pharma? | Current FCF multiple of Maat Pharma is -3.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
